Sino Biopharmaceutical Limited (1177.HK) stock forecast 2027–2029
What is the Sino Biopharmaceutical Limited (1177.HK) stock forecast?
Our forecast for Sino Biopharmaceutical Limited
HK$6.18by November 2027
HK$6.90by November 2029
From HK$5.60 at the November 6, 2026 close, that is a 12 % gain by 2027 and 29 % by 2029, dividends included.
It blends three cases for November 2027, HK$ per share:
- Bear4.3530 % chance
- Base6.2850 % chance
- Bull8.6620 % chance
Our own forecast, built from Sino Biopharmaceutical Limited's filings. It is not an average of analysts' price targets, so it can differ from them.
New accounts get one company's ready report free. No card.
Executive summary + 8 chapters · 20,071 words · 158 sources
Sino Biopharmaceutical Limited (1177.HK) key numbers
Dividend yield is a year of dividends as a share of the price.
- 1.8 %dividend yield
- RMB 19.4 billionrevenue in the quarter to Jun 2026, +11 % on a year earlier
Prices and ratios: our report, at the November 6, 2026 close. Revenue: the company's own figures.
Where could Sino Biopharmaceutical Limited’s shares be by November 2029?
Our weighted price is HK$6.18 in November 2027, implying a 12% return, and HK$6.90 in November 2029, implying a 29% return. Returns include dividends. The bear case carries 30%. The base case carries 50%. The bull case carries 20%.
The weighted price is HK$6.18 in November 2027 and HK$6.53 in November 2028. It reaches HK$6.90 in November 2029. Including dividends, those prices imply returns of 12% and 21% at the first two dates, rising to 29% at the third.
What has to go right or wrong for Sino Biopharmaceutical Limited?
The bear case gives CNY4.3125 billion in 2027 and CNY4.260 billion in 2028, ending at CNY4.1975 billion. It assumes procurement pressure, weak launches and costs absorbing sales growth. The bull case reaches CNY5.475 billion in 2027 and CNY6.400 billion in 2028, ending at CNY7.480 billion. It requires strong uptake, broader access and better conversion of research into sales. Innovative-drug sales already rose from CNY6.05 billion to CNY7.81 billion year on year in the first half of 2026, but selling and R&D costs remain high.
In the bull story, approvals become prescriptions, product mix improves and partner interest validates the pipeline. Stronger cash conversion funds both dividends and buybacks, while recurring earnings support a higher multiple. The shares reach HK$8.66 in November 2027 and HK$13.35 by November 2029. The probability is 20% because the path requires clinical progress, market access and licensing milestones to become repeatable sales rather than one-off receipts.
The forecast's table · base case, then bear / bull in brackets; CNY millions, per share in CNY, unless shown · November 2027
- Earnings4,970 (4,312 / 5,475)
- Shares (millions)18,630 (18,655 / 18,585)
- Dividends per share0.10 (0.07 / 0.12)
- Price to earnings20.00 (16.00 / 25.00)
Bull case, 20 % chance: if it goes right
HK$13.35 by November 2029, +147 % with dividends.
Bear case, 30 % chance: if it goes wrong
HK$3.17 by November 2029, −40 % with dividends.
How much cash does Sino Biopharmaceutical Limited really make?
Free cash flow subtracts capital spending, lease payments and interest from operating cash. Deducting stock-based pay produces a stricter measure because stock awards do not use cash when granted but still dilute shareholders economically. That measure shows how much cash the business generated after making visible that cost.
Sino Biopharmaceutical Limited earnings: how did the last quarter go?
Questions about Sino Biopharmaceutical Limited (1177.HK) stock
Where will Sino Biopharmaceutical Limited stock be in 5 years?
Our report's forecast goes to November 2029. By then it puts the shares between HK$3.17 in the bear case and HK$13.35 in the bull case, and at HK$6.90 with the three cases weighted by their chances. It makes no forecast past November 2029.
Does Sino Biopharmaceutical Limited pay a dividend?
Yes. At the November 6, 2026 close, a year of dividends came to 1.8 % of the share price (our report). Sino Biopharmaceutical Limited dividend →
Who are Sino Biopharmaceutical Limited's competitors?
Our report compares Sino Biopharmaceutical Limited with Innovent.
Why is this forecast different from analysts' price targets?
Analysts' price targets average the share prices that brokerage analysts expect. Our report builds its own three cases from Sino Biopharmaceutical Limited's filings, gives each a chance and counts dividends.
More on Sino Biopharmaceutical Limited (1177.HK)
More Sino Biopharmaceutical Limited pages
Sino Biopharmaceutical Limited's own filings
This page gives the forecast. The report gives the reasons.
The full report: an executive summary and 8 chapters, 20,071 words, 52 tables. Its first page opens here, no account needed.
How it is made: AI reads Sino Biopharmaceutical Limited's filings, writes the report, checks the numbers against them and cites each source, 158 in this one. How we work · Corrections
Read the full report freeNew accounts get one company's ready report free. No card.
Information only, not investment advice. The forecast gives three cases with their chances; it promises no price. Prices are those of the date shown.